Should we give the FDA a Break?

Plant Medicine and CBD Doesn’t Quite Fit Their Standard Operating Procedure The randomized, double-blind controlled studies that became standard in the 1950s for drug clinical trials are not well suited for multi-compound natural products because having more than one bioactive phytocompound exponentially increases the variables that need to be controlled. In fact, the FDA